Tyrosine Protein Kinase Receptor TYRO3 - Pipeline Review, H2 2018 - Research By Markets

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Pipeline Review, H2 2018

VIEW COMPLETE TOC AND LIST OF TABLES & FIGURES:
https://www.researchbymarkets.com/report/tyrosine-protein-kinase-receptor-tyro3-tyrosine-protein-kinase-byk-or-tyrosine-protein-kinase-dtk-or-tyrosine-protein-kinase-rse-or-tyrosine-protein-kinase-tif-or-tyrosine-protein-kinase-sky-or-tyro3-or-ec-27101-2018-27827.html

Summary

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

The latest report Tyrosine Protein Kinase Receptor TYRO3 - Pipeline Review, H2 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) - Tyrosine-protein kinase receptor TYRO3 is an enzyme encoded by the TYRO3 gene. TYRO3 activates the AKT survival pathway, including nuclear translocation of NF-kappa-B and up-regulation of transcription of NF-kappa-B-regulated genes. TYRO3 signaling plays an important role in various processes such as neuron protection from excitotoxic injury, platelet aggregation, cytoskeleton reorganization, inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1, which selectively induces production of suppressors of cytokine signaling SOCS1 and SOCS3. The molecules developed by companies in IND/CTA Filed and Preclinical stages are 1 and 3 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Oncology which include indications Bladder Cancer, Non-Small Cell Lung Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Esophageal Cancer, Gastric Cancer, Melanoma, Metastatic Colorectal Cancer, Ovarian Cancer and Pancreatic Cancer.

Furthermore, this report also reviews key players involved in Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

REQUEST FOR SAMPLE PAGES OF THIS REPORT:
https://www.researchbymarkets.com/sample-request/27827

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) targeted therapeutics

ASK SPECIFIC QUERIES REGARDING THIS REPORT:
https://www.researchbymarkets.com/inquiry/27827

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor TYRO3 (Tyrosine Protein Kinase BYK or Tyrosine Protein Kinase DTK or Tyrosine Protein Kinase RSE or Tyrosine Protein Kinase TIF or Tyrosine Protein Kinase SKY or TYRO3 or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Companies Mentioned
Celldex Therapeutics Inc
Elsalys Biotech SA
Ignyta Inc
Qurient Co Ltd

Contact Us:
Research By Markets
Ritesh Tiwari | Sales
Email: enquiry@researchbymarkets.com

About Us:

"Research By Markets" is a Market Research Reports Depository. Our Latest Market Research Reports cover a lot of Industry Sectors - Aerospace and Defense, Automotive and Transportation, Chemicals and Materials, Consumer Goods and Services, Energy and Power, Environmental, Food and Beverages, Healthcare, Information Technology, Manufacturing and Construction, Medical Devices, Petroleum, Pharmaceuticals, Semiconductor and Electronics, Telecommunications and more.

We are trusted by Fortune 500 companies for our client centric support. We have helped our clients in procuring research studies as per their requirements and also ensured they get proper post purchase support. We ensure that all our client queries are addressed in quick time.

Our website and payment gateway are completely secured to prevent any client information data leak. We do not store any credit card information in our database or emails. We conform to strict security standards and our Technology team works hard to keep our servers secure and protected at all times.

Our Sales Team does not bother clients with phone calls unless requested by the client itself. Nor do we run any email marketing campaigns or bombard clients with repeated follow up emails.

Corporate Clients can also avail discounts. To know more get in touch with us.

We strive our best to ensure that our clients have a seamless experience and are happy and smiling every time they do business with us.

"A satisfied customer is a the best business strategy of all" - Michael LeBoeuf, Business Author.

https://www.researchbymarkets.com/aboutus

Research By Markets
E/3, Ganga Homes,
Behind Bank Of India,
Viman Nagar,
Pune 411 014.
Maharashtra, India

This release was published on openPR.